1 2 3 4 UNITED STATES DISTRICT COURT 5 THE DISTRICT OF NEVADA 6 SPECTRUM PHARMACEUTICALS, INC. Case No.: 2:15-cv-00139-JCM-NJK and UNIVERSITY OF STRATHCLYDE, 7 Plaintiffs, 8 **ORDER** vs. 9 AMNEAL PHARMACEUTICALS LLC 10 Defendant. 11 WHEREAS, on January 23, 2015, Plaintiffs Spectrum Pharmaceuticals, Inc. and 12 University of Strathclyde (collectively, "Plaintiffs") commenced this action against Amneal 13 Pharmaceuticals, Inc. ("Amneal"), alleging infringement of U.S. Patent No. 6,500,829 ("the 14 15 '829 patent'') under 35 U.S.C. § 271(a), (b), (c), and (e)(2)(A) (ECF No. 1); WHEREAS Plaintiffs and Amneal have jointly stipulated to final judgment in this 16 action in accordance with the Stipulation for Entry of Final Judgment. 17 NOW, THEREFORE, IT IS HEREBY ORDERED AS FOLLOWS: 18 Judgment is entered in favor of Amneal that claims 1 and 2 of the '829 patent are 19 invalid, and claims 3, 4, and 5-14 of the '829 patent are not infringed by ANDA No. 207547 as 20 if fully tried and adjudicated. 21 22 IT IS SO ORDERED: 23 **UNITED STATES DISTRICT JUDGE** 24 June 9, 2016 DATED: 25 26 27

360402

28